E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic obstructive pulmonary disease (COPD). |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Classification code | 10009033 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy and safety/tolerability of UK-500,001 DPI in adults with moderate to severe COPD (Global initiative in Obstructive Lung Disease [GOLD] stage II/III). |
|
E.2.2 | Secondary objectives of the trial |
1. To explore the efficacious dose range for UK-500,001 DPI in COPD and provide information for a Phase IIb dose ranging. 2. To evaluate the time course of response to UK-500,001 DPI. 3. To evaluate the persistence of UK-500,001 DPI effects on lung function and symptoms for two weeks after stopping the drug. 4. To evaluate the PK-PD relationship between dose and/or systemic UK-500,001 exposure vs. efficacy and/or safety/tolerability in COPD patients. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Male or female patients between, and including, the ages of 40 and 80 years. Females need to be of either non-childbearing potential; or if of childbearing potential may be included providing they are using acceptable methods of contraception. 2. Patients with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD, 2003 revision) and who meet the following criteria for Stage II III disease: Patients must have a post-bronchodilator FEV1/FVC ratio < 0.7 and a post-bronchodilator FEV1 of 30 - 80% (inclusive) of the predicted value for age, height, race and sex using European Community for Coal and Steel (ECCS) standards, Luxembourg 1993. To qualify for randomization, these criteria must be met at screen and replicated during run in phase. 3. Patients must have a smoking history of at least 10 pack years and meet one of the following criteria: 1) They are current smokers; or 2). They are ex smokers who have abstained from smoking for at least 6 months. Formula for pack-years cigarettes = (average number of cigarettes/day ÷ 20) x years of smoking. Formula for pack-years tobacco = ounces per week x 2/7 x years of smoking. 4. Patients must have stable disease for at least 1 month prior to screening. During the screening and run-in phase patients must be able to manage disease symptoms adequately with short acting bronchodilators only [i.e. inhaled ipratropium bromide 2 actuations (20mg/actuation) QID administered from a MDI +/- salbutamol rescue medication up to a maximum of 8 actuations (100mg/actuation) daily], without reliance on other therapies including oral or inhaled corticosteroids, long acting bronchodilators, nebulizer therapy, theophylline or regular oxygen. 5. Body Mass Index (BMI) < 35 kg/m2 and a total body weight >40 kg. 6. Patients must be able to give informed written consent prior to entering the study. 7. Patients must be willing and able to comply with scheduled visit and all study related procedures. |
|
E.4 | Principal exclusion criteria |
1. More than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalization for the treatment of COPD within 3 months of screening or more than twice during the preceding year. 2. History of a lower respiratory tract infection or significant disease instability during the month preceding screening or during the time between screening and randomization. 3. History or presence of respiratory failure, cor pulmonale or right ventricular failure. 4. Patients with home oxygen therapy (either prn or long term oxygen therapy, LTOT). 5. Any clearly documented history of adult asthma or other chronic respiratory disorders (e.g. bronchiectasis, pulmonary fibrosis, pneumoconiosis). 6. Known previous diagnosis of HIV infection, hepatitis B or C carrier status or chronic active hepatitis of any etiology (specific screening is not required). 7. History of cancer (other than cutaneous basal cell) in the previous 5 years. 8. History within the previous year of: myocardial infarction, cardiac arrhythmia (e.g. atrial fibrillation, paroxysmal atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia), left ventricular failure, unstable angina, coronary angioplasty, coronary artery bypass grafting (CABG) or cerebrovascular accident (including transient ischemic attacks). 9. Active tuberculosis within the previous 2 years. 10. History within the previous 6 months of: a) an epileptic seizure. b) poorly controlled Type 1 or Type 2 diabetes. c) acute hepatitis of any etiology. 11. A major surgical operation within 1 month of screening. 12. Screening systolic blood pressure < 90mmHg. 13. ECG abnormalities at screening or randomization, including those listed below. The investigator will decide whether ECG abnormalities other than those listed are clinically significant and should exclude the patient from enrollment. a) Predominant heart rhythm other than normal sinus rhythm e.g. atrial fibrillation, atrial flutter, supraventricular tachycardia. b) Patients with pre randomization evidence of QTc prolongation (defined as >450 msec for men; >470 msec for women) are not eligible for randomization without Pfizer approval. This assessment is made by the investigator at the time of ECG collection. c) Atrioventricular (AV) block greater than first degree. d) Resting heart rate >100 or <40 bpm. e) Evidence of previous myocardial infarction or significant ischemic changes in the absence of clinical history consistent with these findings. 14. History or evidence, based upon a complete medical history, full physical examination, posterior anterior chest X ray (within last 12 months), 12 lead resting ECG or clinical laboratory test results, of any other significant concomitant clinical disease that, in the opinion of the investigator, could interfere with the conduct, safety or interpretation of results of this study. Patients with certain chronic conditions such as hypertension, thyroid disease, Type 1 or Type 2 diabetes, hypercholesterolemia, gastroesophageal reflux, or depression may be included in the study as long as the conditions are well controlled and medications relating to the condition are stable and would not be predicted to compromise safety or interfere with the tests and interpretations of this study. 15. Female patients of childbearing potential who are unwilling or unable to use an acceptable method of contraception from screening until completion of follow-up procedures. 16. Use of any investigational drug other than UK-500,001 during this study, or within 1 month prior to screening. Note: Prior exposure to a PDE4 inhibitor during a clinical study is permitted, as long as the patient completed PDE4 inhibitor dosing in the clinical study at least 1 month prior to screening. 17. Use of any of the prohibited medications within the indicated time frame prior to the start of screening (see protocol Section 5.5 for details). 18. History of severe drug induced hypersensitivity (i.e. anaphylaxis). 19. Known lactose intolerance or contraindicated for rescue/maintenance medication. 20. Pregnant or nursing females, or females intending to become pregnant during the course of the study. 21. Donation or intent to donate blood, or blood components during the study or within 1 month after completion of the study. 22. Evidence of alcohol or drug abuse or dependency (specific screening is not required). 23. Inability to fill, and inhale correctly from, the single pin monodose capsule inhaler device for any reason. 24. Inability to comprehend, or unwillingness to follow, the study requirements including attendance at out patient clinic visits and participation in laboratory testing as called for by the protocol. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Mean change from baseline in trough (prior to administration of study drug) FEV1 at Week 6. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |